Table 4.

Univariate and multivariate logistic regression analyses for overall survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors after propensity score matching.

Variable	Category	Univariate analysis		Multivariate analysis
		HR (95% CI)	p-value	HR (95% CI)	p-value
Age, years	⩾61 versus <61	0.86 (0.62−1.18)	0.37	0.82 (0.59−1.15)	0.26
Sex	Female versus male	1.33 (0.98−1.98)	0.06	1.59 (0.97−2.60)	0.06
Smoking history	Yes versus no	0.94 (0.68−1.30)	0.73	1.50 (0.95−2.37)	0.08
Histology	Squamous versus non-squamous	0.84 (0.59−1.19)	0.34	0.76 (0.52−1.12)	0.17
Stage	IV versus III	1.17 (0.71−1.92)	0.53	0.83 (0.48−1.42)	0.51
ECOG PS	⩾2 versus 0−1	1.25 (0.67−2.31)	0.48	1.17 (0.60−2.26)	0.64
Treatment type	Combination therapy versus monotherapy	0.64 (0.46−0.88)	0.01	0.64 (0.45−0.91)	0.01
Prior lines of therapy	1 line versus 2 lines versus ⩾3 lines	1.38 (1.12−1.69)	<0.01	1.28 (1.01−1.63)	0.04
Brain metastasis	Yes versus no	2.00 (1.35−2.95)	<0.01	1.63 (1.08−2.47)	0.02
Baseline Hb, g/L	⩾110 versus <110	0.56 (0.40−0.77)	<0.01	0.59 (0.43−0.83)	<0.01

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; Hb, hemoglobin; HR, hazard ratio.